Efficacy and safety of serplulimab in solid tumors: a meta-analysis
ObjectiveThe goal of this study was to investigate the effectiveness and safety of serplulimab in advanced solid tumors through a meta-analysis approach.MethodsAn electronic search was conducted across the Embase, Web of Science, PubMed, and Cochrane Library databases, covering the period from each...
Saved in:
| Main Authors: | Peimeng Shen, Tao Zhang, Lina Hao, Ming Jing, Yanxin Wu, Shuwen Yu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1604874/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world first-line serplulimab therapy for advanced esophageal cancer: effectiveness, safety, and clinical implications
by: Fei Yan, et al.
Published: (2025-08-01) -
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial
by: Ying Cheng, et al.
Published: (2025-08-01) -
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01) -
Efficacy and safety of rituximab in children with steroid-dependent or frequently relapsing nephrotic syndrome: a meta-analysis of randomized controlled trials
by: Ningxin Luo, et al.
Published: (2023-02-01) -
HLX07 alone or combined with serplulimab, cisplatin and 5‐fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study
by: Yun Liu, et al.
Published: (2024-12-01)